Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day moving average of $62.25 and traded as low as $61.46. Vaxcyte shares last traded at $61.61, with a volume of 707,762 shares trading hands.
Specifically, insider Harpreet Dhaliwal sold 17,000 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were sold at an average price of $67.83, for a total value of $1,153,110.00. Following the completion of the transaction, the insider owned 68,085 shares of the company’s stock, valued at $4,618,205.55. The trade was a 19.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Analyst Ratings Changes
A number of analysts recently commented on PCVX shares. Guggenheim upped their price objective on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Bank of America reduced their target price on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a report on Monday, September 28th. Zacks Research raised Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $120.00 price target on shares of Vaxcyte in a research report on Monday, October 12th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Vaxcyte presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.50.
Vaxcyte Price Performance
The company’s 50-day moving average price is $62.25 and its 200-day moving average price is $57.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.56 and a quick ratio of 4.56. The company has a market cap of $9.75 billion, a P/E ratio of -7.64 and a beta of 1.31.
Vaxcyte (NASDAQ:PCVX – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($1.99) EPS for the quarter, topping analysts’ consensus estimates of ($2.11) by $0.12. During the same quarter last year, the business earned ($1.56) EPS. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -7.51 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Vaxcyte
Large investors have recently added to or reduced their stakes in the company. Bellevue Group AG raised its stake in shares of Vaxcyte by 17.8% in the 3rd quarter. Bellevue Group AG now owns 2,322,401 shares of the company’s stock valued at $132,145,000 after purchasing an additional 350,466 shares during the period. Cetera Investment Advisers lifted its holdings in shares of Vaxcyte by 26.6% in the third quarter. Cetera Investment Advisers now owns 13,117 shares of the company’s stock valued at $746,000 after purchasing an additional 2,755 shares in the last quarter. FORA Capital LLC acquired a new position in shares of Vaxcyte during the third quarter worth about $246,000. Pathstone Holdings LLC boosted its position in shares of Vaxcyte by 61.2% during the third quarter. Pathstone Holdings LLC now owns 38,482 shares of the company’s stock worth $2,400,000 after buying an additional 14,606 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Vaxcyte during the third quarter worth about $18,999,000. Institutional investors own 96.78% of the company’s stock.
Vaxcyte Company Profile
Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.
See Also
- Five stocks we like better than Vaxcyte
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.
